Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer (BEVAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02250118
Recruitment Status : Terminated (Insufficient Recruitment)
First Posted : September 26, 2014
Last Update Posted : November 6, 2017
Henri Mondor University Hospital
Information provided by (Responsible Party):
Institut Curie

Brief Summary:

Metastatic pleural effusion is a common complication of late-stage cancer and reduces the quality of life and survival of patients. The survival of patients with recurrent pleurisy by uncontrolled local or systemic treatment is less than 6 months. It is important to develop specific therapies to improve the quality of life and survival of patients with metastatic pleurisy.

Bevacizumab is a monoclonal anti vascular endothelial growth factor (VEGF) which has proven effective in many indications in oncology. Vascular endothelial growth factor (VEGF) is an angiogenic factor which increases endothelial permeability. It plays a central role in many tumors of epithelial origin. In this context, it is legitimate to ask whether an antiangiogenic targeting VEGF may be effective in patients with metastatic pleurisy by decreasing local blood supply and over-permeability.

No study has been interested in the intra-pleural pharmacokinetics of monoclonal antibodies and there are no predictive or prognostic biomarkers for metastatic pleural effusions.

The investigators believe that intrapleural administration of bevacizumab will reduce the pleural vasculature permeability. It will neutralize VEGF present in pleural fluid and reduce the replenishment of effusion due to its prolonged half-life of 21 days.

The investigators therefore propose a phase I study to determine the maximum tolerated dose and the recommended dose for phases II, studying the pharmacokinetics of intrapleural bevacizumab administered by an implantable device after evacuating a symptomatic metastatic pleurisy as part of a mammary carcinoma. The VEGF intrapleural levels and serum will be study and the time until a new puncture. Dyspnea will be evaluated as well as its impact on quality of life.

Condition or disease Intervention/treatment Phase
Pleural Effusion, Malignant Breast Cancer Drug: Bevacizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study to Determine the Maximum Tolerated Dose and Evaluate the Pharmacokinetics of Intrapleural Bevacizumab After Pleural Drainage in Patients With Symptomatic Malignant Pleural Effusion in the Context of Breast Cancer
Actual Study Start Date : December 9, 2014
Actual Primary Completion Date : April 12, 2017
Actual Study Completion Date : October 17, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Bevacizumab
Intrapleural use: range 0.5 - 5 mg/kg
Drug: Bevacizumab
Intrapleural Bevacizumab
Other Name: Avastin

Primary Outcome Measures :
  1. To determine the maximum tolerated dose (MTD) [ Time Frame: 90 days after intrapleural injection ]
    Maximum tolerated dose (MTD) according to safety of intrapleural bevacizumab at dose levels of 1 mg/kg, 3 mg/kg and 5 mg/kg administered by pleural catheter after drainage of symptomatic malignant pleural effusion in a context of breast cancer.

Secondary Outcome Measures :
  1. Study of the pleural and serum pharmacokinetics [ Time Frame: 90 days ]
    Pharmacokinetics of bevacizumab just before administration and 1 hour after treatment on Day 1, and at D15, D30, D60 and D90.

  2. Study of pleural and serum Vascular Endothelial Growth Factor (VEGF) levels [ Time Frame: 90 days ]
    Pleural and serum VEGF levels just before administration and 1 hour after treatment on Day 1, and at D15, D30, D60 and D90.

  3. Determination of time until new punction or death [ Time Frame: 2 years ]
    Response to treatment assessed by the time to new puncture

  4. Total number of pleural drainage procedures [ Time Frame: 90 days ]
    Measure of the total number of pleural drainage procedures at D15, D30, D60 and D90.

  5. Drainage-free survival and overall survival [ Time Frame: 2 years ]
    Drainage-free survival and overall survival Evaluation of survival without punction and overall survival

  6. Evaluation of dyspnoea [ Time Frame: 90 days ]
    Measure by dyspnoea scale and peak flow at D15, D30, D60 and D90

  7. Evaluation of quality of life [ Time Frame: 2 years ]
    Quality of life (QLQ-C30) questionnaire according to European Organisation for Research and Treatment of Cancer (EORTC) and FACIT questionnaire Dyspnoea 10 Short Form at D15, D30, D60 and D90 and every 6 month during 2 years

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient with histologically documented pleural effusion in a type of breast carcinoma in exudate or with no other identified cause. In the absence of positive cytology, will ensure that there is no other cause of the patient's history may explain the effusion.
  2. Unilateral or bilateral malignant pleural effusion but requiring drainage on only one side.
  3. Patient presenting an indication for pleural implantable device, means that requiring at least one pleural drainage.
  4. Patient aged 18 years old or more and without measure of legal protection
  5. Subject female or male
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2
  7. Expected life span > 2 months
  8. Corticosteroids authorized if started less than 15 days before enrollment and no dose modification will be allowed during treatment
  9. Adequate biological functions 14 days before inclusion:

    • Haemoglobin ≥ 8 g/dl (transfusion authorized)
    • Neutrophil count (ANC) ≥ 1000/mm3
    • Platelet count ≥ 100 000/mm3
    • International Normalized Ratio (INR) ≤ 1.5 and/or Prothrombin Ratio (TR) ≥ 70 % and Partial Thromboplastin Time (PTT) ≤ 1.5
    • Aspartate Aminotransferase Test (AST), Alanine Aminotransferase Test (ALT), Gamma-Glutamyl Transpeptidase (GGT), Alk Phos ≤ 3 times Unit Line Number (ULN), bilirubin ≤ 40 μmol/L
    • Lactate Dehydrogenase (LDH) ≤ 1,5 times ULN
    • Albumin ≥ 28 g/dL
    • Creatinine clearance ≥ 45 mL/min according to the Modification of the Diet in Renal Disease formula (MDRD)
    • Proteinuria ≤ 1g/dL in the absence of tract infection
  10. Cardiac Function satisfactory: Left Ventricular Ejection Fraction (LVEF) determined by myocardial scintigraphy or echocardiography
  11. Females of childbearing potential must take acceptable methods of birth control during the complete duration of treatment and serum pregnancy tests must be negative at the inclusion. Men must agree to use a condom if his partner is of child bearing potential
  12. Patient receiving a social security system
  13. Signed inform consent

Exclusion Criteria:

  1. Pregnant or lactating women or childbearing potential refusing methods of birth control
  2. Transudative pleural effusion: pleural protein < 30 g/L and/or Light's criteria when pleural protein is not indicative. Light's criteria are as follows (for diagnosis of transudative):

    • Pleural protein/serum protein ratio < 0.5
    • Pleural LDH/serum LDH ratio < 0.6
    • Pleural LDH < two-thirds the upper limit of normal of serum LDH
  3. Purulent pleural effusion.
  4. Macroscopically haemorrhagic pleural effusion.
  5. Bilateral metastasis pleurisy requiring punctures on both sides.
  6. Any co morbidity considered to be incompatible with participation in the study, according to the investigator, particularly: untreated infectious disease, chronic respiratory insufficiency, chronic renal insufficiency, Child Pugh B or C, hepatocellular insufficiency; chronic heart failure not controlled by appropriate medical treatment.
  7. Contraindications to intrapleural administration of bevacizumab:

    • Non-controlled arterial or venous thromboembolism
    • Major surgery during the previous month or planned after study
    • Known, non treated brain metastases
    • Known hypersensitivity to bevacizumab or one of its excipients
    • Hypersensitivity to Chinese hamster ovary cell (CHO) products or other human recombinant or humanized antibodies
    • Intravenous administration of bevacizumab planned or underway in the usual cancer treatment (≥ 3 weeks wash out from the intrapleural injection)
    • Radiotherapy including lung field concerned since the administration of the product until the end of the study.
  8. Diagnosis of any second malignancy within the last 5 years, except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for > 3 years.
  9. Patients can't participate in another clinical trial with another experimental anti-cancer drug therapy simultaneously for 90 days. No exclusion period is required after the end of the trial visit.
  10. Impossibility to follow the calendar of exams because of geographic, social or psychological reasons.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02250118

Layout table for location information
Institut Curie - Hôpital René Huguenin
Saint-Cloud, France, 92210
Sponsors and Collaborators
Institut Curie
Henri Mondor University Hospital
Layout table for investigator information
Principal Investigator: Maya Gutierrez, MD Institut Curie - Hôpital René Huguenin

Layout table for additonal information
Responsible Party: Institut Curie Identifier: NCT02250118    
Other Study ID Numbers: IC 2014-02
2014-000654-11 ( EudraCT Number )
First Posted: September 26, 2014    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: May 2017
Keywords provided by Institut Curie:
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Pleural Effusion, Malignant
Pleural Effusion
Neoplasms by Site
Breast Diseases
Skin Diseases
Pleural Diseases
Respiratory Tract Diseases
Pleural Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors